Early in Vitro and in Vivo development of high-level daptomycin resistance is common in mitis group streptococci after exposure to daptomycin

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 5, 2013, Pages 2319-2325

  García De La Mària, Cristina ^a   Pericas, Juan M ^a   Del Río, Ana ^a   Castañeda, Ximena ^a   Vila Farrés, Xavier ^a   Armero, Yolanda ^a   Espinal, Paula A ^a   Cervera, Carlos ^a   Soy, Dolors ^a   Falces, Carlos ^a   Ninot, Salvador ^a   Almela, Manel ^a   Mestres, Carlos A ^a   Gatell, Jose M ^a   Vila, Jordi ^a,b   Moreno, Asuncion ^a   Marco, Francesc ^a   Miró, Jose M ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DAPTOMYCIN; GENTAMICIN; PENICILLIN DERIVATIVE; VANCOMYCIN;

ADD ON THERAPY; ALPHA HEMOLYTIC STREPTOCOCCUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL ENDOCARDITIS; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATION; CONTROLLED STUDY; DRUG EXPOSURE; EXPERIMENTAL RABBIT; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STREPTOCOCCUS ANGINOSUS; STREPTOCOCCUS BOVIS; STREPTOCOCCUS MITIS; STREPTOCOCCUS MUTANS; STREPTOCOCCUS SALIVARIUS;

ANIMALS; ANTI-BACTERIAL AGENTS; DAPTOMYCIN; DRUG RESISTANCE, BACTERIAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ENDOCARDITIS, BACTERIAL; GENTAMICINS; HUMANS; MICROBIAL SENSITIVITY TESTS; RABBITS; SPECIES SPECIFICITY; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS ANGINOSUS; STREPTOCOCCUS BOVIS; STREPTOCOCCUS MITIS; STREPTOCOCCUS MUTANS; VANCOMYCIN;

EID: 84876277327     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01921-12     Document Type: Article

References (36)

1. Bruckner L, Gigliotti F. 2006. Viridans group streptococcal infections among children with cancer and the importance of emerging antibiotic resistance. Semin. Pediatr. Infect. Dis. 17:153-160.
2. Presterl E, Grisold AJ, Reichmann S, Hirschl AM, Georgopoulos A, Graninger W. 2005. Viridans streptococci in endocarditis and neutropenic sepsis: biofilm formation and effects of antibiotics. J. Antimicrob. Chemother. 55:45-50.
3. Murdoch DR, Corey GR, Hoen B, Miró JM, Fowler VG, Jr, Bayer AS, Karchmer AW, Olaison L, Pappas PA, Moreillon P, Chambers ST, Chu VH, Falcó V, Holland DJ, Jones P, Klein JL, Raymond NJ, Read KM, Tripodi MF, Utili R, Wang A, Woods CW, Cabell CH, International Collaboration on Endocarditis-Prospective Cohort Study (ICE-PCS) Investigators. 2009. Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective Cohort Study. Arch. Intern. Med. 169:463-473.
4. Knoll B, Tleyjeh IM, Steckelberg JM, Wilson WR, Baddour L. 2007. Infective endocarditis due to penicillin-resistant viridans group streptococci. Clin. Infect. Dis. 44:1585-1592.
5. Seppälä H, Haanperä M, Al-Juhaish M, Järvinen Jalava HJ, Huovinen P. 2003. Antimicrobial susceptibility patterns and macrolide resistance genes of viridans group streptococci from normal flora. J. Antimicrob. Chemother. 52:636-644.
6. Westling K, Julander I, Ljungman P, Heimdahl A, Thalme A, Nord CE. 2004. Reduced susceptibility to penicillin of viridans group streptococci in the oral cavity of patients with haematological disease. Clin. Microbiol. Infect. 10:899-903.
7. Levy CS, Kogulan P, Gill VJ, Croxton MB, Kane JG, Lucey DR. 2001. Endocarditis caused by penicillin-resistant viridans streptococci: 2 cases and controversies in therapy. Clin. Infect. Dis. 33:577-579.
8. Baddour LM, Wilson WR, Bayer AS, Fowler VG, Jr, Bolger AF, Levison ME, Ferrieri P, Gerber MA, Tani LY, Gewitz MH, Tong DC, Steckelberg JM, Baltimore RS, Shulman ST, Burns JC, Falace DA, Newburger JW, Pallasch TJ, Takahashi M, Taubert KA, Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association, Infectious Diseases Society of America. 2005. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 111: e394-e434.
9. Gould FK, Denning DW, Elliott TS, Foweraker J, Perry JD, Prendergast BD, Sandoe JA, Spry MJ, Watkin RW. 2012. Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: a report of the Working Party of the British Society for Antimicrobial Chemotherapy. J. Antimicrob. Chemother. 67:269-289.
10. Habib G, Hoen B, Tornos P, Thuny F, Prendergast B, Vilacosta I, Moreillon P, de Jesus Antunes M, Thilen U, Lekakis J, Lengyel M, Müller L, Naber CK, Nihoyannopoulos P, Moritz A, Zamorano JL. 2009. Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009). Eur. Heart J. 30:2369-2413.
11. Streit JM, Steenbergen JN, Thorne GM, Alder J, Jones RN. 2005. Daptomycin tested against 915 bloodstream isolates of viridans group streptococci (eight species) and Streptococcus bovis. J. Antimicrob. Chemother. 55:574-578.
12. Cervera C, Castañeda X, Pericas JM, del Río A, García de la Mària C, Mestres C, Falces C, Marco F, Moreno A, Miró JM. 2011. Clinical utility of daptomycin in infective endocarditis caused by Gram-positive cocci. Int. J. Antimicrob. Agents 38:365-370.
13. Fowler VG, Jr, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, Levine DP, Chambers HF, Tally FP, Vigliani GA, Cabell CH, Link AS, DeMeyer I, Filler SG, Zervos M, Cook P, Parsonnet J, Bernstein JM, Price CS, Forrest GN, Fätkenheuer G, Gareca M, Rehm SJ, Brodt HR, Tice A, Cosgrove SE. 2006. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N. Engl. J. Med. 355:653-665.
14. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, Rybak MJ, Talan DA, Chambers HF. 2011. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: Executive summary. Clin. Infect. Dis. 52:e18-e55.
15. Larioza J, Girard A, Brown RB. 2011. Clinical experience with daptomycin for outpatient parenteral antibiotic therapy. Am. J. Med. Sci. 342:486-488.
16. Nathwani, D. 2009. Developments in outpatient parenteral antimicrobial therapy (OPAT) for gram-positive infections in Europe, and the potential impact of daptomycin. J. Antimicrob. Chemother. 64:447-453.
17. Miró JM, García de la Mària C, Vila-Farrés X, Castañeda X, Espinal P, Armero Y, Cervera C, Soy D, del Río A, Falces C, Ninot S, Almela M, Mestres CA, Gatell JM, Jiménez de Anta MT, Moreno A, Vila J, Marco F, the Hospital Endocarditis Study Group. 2011. Addition of gentamicin (GEN) to daptomycin (DAP) prevents the development of high-level DAP-resistance (HLDR) in the treatment of penicillin (PEN)-resistant Streptococcus mitis in a rabbit model of experimental endocarditis (EE), abstr B-051. Abstr. 51st Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
18. Vila-Farrés X, Espinal P, García de de Maria C, Cervera C, del Río A, Almela M, Moreno A, Marco F, Miro JM, Vila J, the Hospital Clinic Endocarditis Study Group. 2011. Analysis of the mechanism explaining the increase in the susceptibility to penicillin in a daptomycin-resistant mutant, which emerges from a penicillin-resistant/daptomycinsusceptible S. mitis strain after 48 hours of daptomycin treatment in a model of experimental endocarditis, abstr C1-1772. Abstr. 51st Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
19. Miró JM, García de la Mària C, Vila-Farrés X, Castañeda X, Espinal P, Armero Y, Cervera C, Soy D, del Río A, Falces C, Ninot S, Almela M, Mestres CA, Gatell JM, Jiménez de Anta MT, Moreno A, Vila J, Marco F, the Hospital Endocarditis Study Group. 2011. Development of high level daptomycin resistance (HLDR) in Streptococcus mitis group bloodstream isolates recovered from patients with infective endocarditis (IE), abstr E-1318. Abstr. 51st Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
20. Cubist Pharmaceuticals. 2008. Cubicin (daptomycin for injection) prescribing information. Cubist Pharmaceuticals, Inc., Lexington, MA.
21. CLSI. 2006. Performance standards for antimicrobial susceptibility testing. Approved standard M100-S16. CLSI, Wayne, PA.
22. Eliopoulos G, Moellering R. 1996. Antimicrobial combinations, p 330-396. In Lorian V (ed), Antibiotics in laboratory medicine. William and Wilkins, Co., Baltimore, MD.
23. Isenberg HD. 2004. Clinical microbiology procedures handbook. ASM Press, Washington, DC.
24. Miró JM, García-de la-Mària C, Armero Y, Soy D, Moreno A, del Río A, Almela M, Sarasa M, Mestres CA, Gatell JM, Jiménez de Anta MT, Marco F, Hospital Clinic Experimental Endocarditis Study Group. 2009. Addition of gentamicin or rifampin does not enhance the effectiveness of daptomycin in the treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 53:4172-4177.
25. Miró JM, García-de la-Mària C, Armero Y, de-Lazzari E, Soy D, Moreno A, del Rio A, Almela M, Mestres CA, Gatell JM, Jiménez-de- Anta MT, Marco F, Hospital Clinic Experimental Endocarditis Study Group. 2007. Efficacy of televancin in the treatment of experimental en- docarditis due to glycopeptide-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 51:2373-2377.
26. Marco F, García-de la-Mària C, Armero Y, Amat E, Soy D, Moreno A, del Río A, Almela M, Mestres CA, Gatell JM, Jiménez de Anta MT, Miró JM, Hospital Clinic Experimental Endocarditis Study Group. 2008. Daptomycin is effective in treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 52:2538-2543.
27. Garrison PK, Freedman LR. 1970. Experimental endocarditis. I. Staphylococcal endocarditis in rabbits resulting from placement of a polyethylene catheter in the right side of the heart. Yale J. Biol. Med. 42:394-410.
28. Loza E, Morosini MI, Pascual A, Tubau F, Alcalá J, Liñares J, Hernández- Bello JR, Baquero F, Perea E, Martín R, Jones RN, Cantón R, Surveillance Program SENTRY, Spain (2002-2006). 2008. Comparative in vitro activity of daptomycin against gram-positive microorganisms: SENTRY surveillance program, Spain (2002-2006). Enferm. Infecc. Microbiol. Clin. 26:489-494. (In Spanish.)
29. Pfaller MA, Sader HS, Jones RN. 2007. Evaluation of the in vitro activity of daptomycin against 19615 clinical isolates of Gram-positive cocci collected in North American hospitals (2002-2005). Diagn. Microbiol. Infect. Dis. 57:459-465.
30. Sader HS, Fritsche TR, Jones RN. 2008. Frequency of occurrence and daptomycin susceptibility rates of gram-positive organisms causing bloodstream infections in cancer patients. J. Chemother. 20:570-576.
31. Akins R. 2011. In vitro development of high-level resistant viridans group streptococci upon exposure to daptomycin, abstr P-951. Abstr. 21st Eur. Conf. Microbiol. Infect. Dis., Milan, Italy, 7 to 10 May 2011.
32. Li T, Mortin LI, Zhang S, Van Praagh A, Chen L, Zhang X, Alder J. 2005. Bactericidal efficacy of daptomycin (DAP) in rat fibrin clot model versus clinical viridans group streptococcus (VGS) strains, abstr 534. Abstr. 43rd Annu. Meet. Infect. Dis. Soc. Am., San Francisco, CA, 6 to 9 October 2005.
33. Arias CA, Panesso D, McGrath DM, Quin X, Mojica MF, Miller C, Diaz L, Tran TT, Rinco S, Barbu ME, Reyes J, Roh JH, Lobos E, Sodergren E, Pasqualini R, Arap W, Quinn PJ, Shamoo Y, Murran BE, Winstock GM. 2011. Genetic basis of in vivo daptomycin resistance in enterococci. N. Engl. J. Med. 365:892-900.
34. Palmer K, Daniel A, Hardy C, Siverman J, Gilmore M. 2011. Genetic basis for daptomycin resistance in enterococci. Antimicrob. Agents Chemother. 55:3345-3356.
35. Palacios F, Lewis JS, Sadkowski L, Echevarria K, Jorgensen JH. 2011. Breakthrough bacteremia and septic shock due to Streptococcus anginosus resistant to daptomycin in a patient receiving daptomycin therapy. Antimicrob. Agents Chemother. 55:3639-3640.
36. Tascini C, Di Paolo A, Poletti R, Flammini S, Emdin M, Ciullo I, Tagliaferri E, Moter A, Menichetti F. 2013. Daptomycin concentrations in valve tissue and vegetation in patients with bacterial endocarditis. Antimicrob. Agents Chemother. 57:601-602.